Voriconazole therapeutic drug monitoring

被引：297

作者：

Smith, J

Safdar, N

Knasinski, V

Simmons, W

Bhavnani, SM

Ambrose, PG

Andes, D

机构：

[1] Univ Wisconsin, Dept Med, Infect Dis Sect, Madison, WI USA

[2] Univ Wisconsin, Dept Pharm, Madison, WI USA

[3] Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI USA

[4] Ordway Res Inst, Inst Clin Pharmacodynam, Albany, NY USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2006年 / 50卷 / 04期

关键词：

D O I：

10.1128/AAC.50.4.1570-1572.2006

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We report on 28 patients who underwent voriconazole monitoring because of disease progression or toxicity. A relationship (P < 0.025) between disease progression and drug concentration was detected. Favorable responses were observed in 10/10 patients with concentrations above 2.05 mu g/ml, while disease progressed in 44% (n = 18) of patients with concentrations below 2.05 mu g/ml.

引用

收藏

页码：1570 / 1572

页数：3

相关论文

共 29 条

[1] Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazol [J].

Alexander, BD ;

Schell, WA ;

Miller, JL ;

Long, GD ;

Perfect, JR .

TRANSPLANTATION, 2005, 80 (06) :868-871

[2] Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].

Ambrose, PG ;

Grasela, DM ;

Grasela, TH ;

Passarell, J ;

Mayer, HB ;

Pierce, PF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797

[3] The therapeutic monitoring of antimicrobial agents [J].

Begg, EJ ;

Barclay, ML ;

Kirkpatrick, CJM .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (01) :23-30

[4] Pharmacokinetics and pharmacodynamics of antibiotics in otitis media [J].

Craig, WA ;

Andes, D .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (03) :255-259

[5]

DELAVEGA SL, 1994, DRUG EXP CLIN RES, V20, P69

[6] Clinical significance of the cytochrome P4502C19 genetic polymorphism [J].

Desta, Z ;

Zhao, XJ ;

Shin, JG ;

Flockhart, DA .

CLINICAL PHARMACOKINETICS, 2002, 41 (12) :913-958

[7]

*EUR MED AG, 2002, EPAR VFEND

[8] PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS [J].

FORREST, A ;

NIX, DE ;

BALLOW, CH ;

GOSS, TF ;

BIRMINGHAM, MC ;

SCHENTAG, JJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1073-1081

[9] EVOLVING ROLE OF FLUCYTOSINE IN IMMUNOCOMPROMISED PATIENTS - NEW INSIGHTS INTO SAFETY, PHARMACOKINETICS, AND ANTIFUNGAL THERAPY [J].

FRANCIS, P ;

WALSH, TJ .

CLINICAL INFECTIOUS DISEASES, 1992, 15 (06) :1003-1018

[10] Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole [J].

Glasmacher, A ;

Hahn, C ;

Leutner, C ;

Molitor, E ;

Wardelmann, E ;

Losem, C ;

Sauerbruch, T ;

Marklein, G ;

Schmidt-Wolf, IGH .

MYCOSES, 1999, 42 (7-8) :443-451